ImmunoCellular Therapeutics (IMUC) 8-K ImmunoCellular Therapeutics Announces Fourth Quarter

Condensed Balance Sheets
		12/31/2012		12/31/2011
Cash	$	26,216,668	$	6,653,168
Other current assets		714,508		91,286
Non current assets		88,025		406,303
	$	27,019,201	$	7,150,757
Current liabilities	$	1,098,307	$	1,761,289
Warrant liabilities		2,852,880		2,157,408
Shareholders' equity		23,068,014		3,232,060
	$	27,019,201	$	7,150,757
Condensed Statement of Operations
		Year		Year
		ended		ended
		12/31/2012		12/31/2011
Revenue	$	-	$	-
Research and development		7,711,233		4,988,612
Stock based compensation		496,007		1,190,133
General and administrative		3,619,291		2,446,757
Loss before other expenses		(11,826,531)		(8,625,502)
Interest income		8,609		4,346
Financing expense		(397,294)		-
Change in fair value of warrant liabilities		(2,279,923)		2,901,253
Net loss		(14,495,139)		(5,719,903)
Deemed dividend on preferred stock		0		0
Net loss available to common stockholders	$	(14,495,139)	$	(5,719,903)